276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)
Authors:
- S.M. TolaneySTS.M. Tolaney
- E. de AzambujaEAE. de Azambuja
- L.A. EmensLEL.A. Emens
- S. LoiSLS. Loi
- W. PanWPW. Pan
- J. HuangJHJ. Huang
- S.W. SunSSS.W. Sun
- C. LaiCLC. Lai
- P. SchmidPSP. Schmid
- 13 September 2022
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 33 (7) , S664-S665